Shikari® (S-ATC) Anti-Cetuximab ELISA w/confirmation
CET-QNS-ERB
Enzyme immunoassay for the quantitative determination of antibodies to Cetuximab (Erbitux®) in serum and plasma with confirmation.
This kit has been especially developed for the quantitative antibodies to cetuximab in serum and plasma samples
Cetuximab (Erbitux®) was associated to the development of anti-Cetuximab antibodies, even some were reported to be neutralizing, in various percentages of patients during therapy with the drug EGFR®. This might lead to severe complications. This kit can be efficiently used for monitoring anti-Cetuximab antibodies during therapy and offers the clinician a tool for decision on possible preventive measures such as possible addition of immunosuppressive drug to reduce anti-Cetuximab antibodies. .
All SHIKARI® ELISA kits are suitable for biosimilar work.
All SHIKARI® ELISA kits are produced under ISO 13485 quality system and have CE IVD mark.
For technical inquiry, please contact techsupport@matriksbiotek.com
| Required Volume (µl) | 20 |
| Total Time (min) | 140 |
| Sample | Serum, plasma |
| Sample Number | 96 |
| Detection Limit (ng/mL) | 30 |
| Spike Recovery (%) | Between 85-115 |
| Shelf Life (year) | 1 |
| Assay type | Quantitative |
| Species Reactivity | Human |
| Storage conditions | Store at +4°C. Please refer to protocols. |
| Shipping conditions | At room temperature |
| # | File | Action |
|---|---|---|
| Instructions For Use | Download | |
| Safety Data Sheet (SDS) | Download | |
| Validation Report | Download |
Publications with this drug
| # | File | Action |
|---|---|---|
| Peña-Cabia, Silvia, et al. "Assessment of exposure-response relationship for cetuximab in patients with metastatic colorectal cancer and head and neck cancer." Farmacia Hospitalaria: Organo Oficial de Expresion Cientifica de la Sociedad Espanola de Farmacia Hospitalaria 46.1 (2021): 21-26. | Visit Link | |
| Zhang, Jinhua, et al. "sRNA-based screening chromosomal gene targets and modular designing Escherichia coli for high-titer production of aglycosylated immunoglobulin G." ACS Synthetic Biology (2020). | Visit Link | |
| Zhang, Jinhua, et al. "Synthetic sRNA‐based Engineering of Escherichia coli for Enhanced Production of Full‐length Immunoglobulin G." Biotechnology Journal (2020): 1900363. | Visit Link | |
| Kaito Shibata, et al. Simple and rapid LC-MS/MS method for the absolute determination of cetuximab in human serum using an immobilized trypsin Journal of Pharmaceutical and Biomedical Analysis Volume 146, Pages 266-272, 30 November 2017 | Visit Link | |
| Evaluación de la relación exposición-respuesta de bevacizumab y de cetuximab en cáncer colorrectal metastásico y de cetuximab en cáncer de cabeza y cuello Silvia Peña Cabia | Visit Link |